No Data
No Data
Oppenheimer Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Raises Target Price to $40
ARS Pharmaceuticals Initiated With an Outperform at Oppenheimer
Oppenheimer Initiates ARS Pharmaceuticals at Outperform
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
Express News | ARS Pharmaceuticals Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing
ARS Pharmaceuticals on Track for Record Winning Streak -- Data Talk